NE-ADJUVANCE-TECH
Adjuvance Technologies Inc., a privately held clinical-stage biopharmaceutical company developing saponin adjuvants and vaccines for infectious disease and immuno-oncology, announced that its adjuvant TQL-1055 was safe and well-tolerated with a co-administered pertussis vaccine. This is the first clinical trial of a candidate from the company’s adjuvant and vaccine portfolio.
“The usefulness of saponin adjuvants has been constrained by dose-limiting tolerability and manufacturing challenges. Our semi-synthetic molecule is designed to overcome these limitations,” said Tyler Martin M.D., Chief Executive Officer at Adjuvance. “These promising interim results demonstrate the potential of TQL-1055, including its ability to be used in a broader dose-range without compromising its excellent tolerability.”
Interim data from the trial show that TQL-1055 was generally well tolerated across all dose levels, with an overall safety profile similar to a commercial pertussis vaccine. Solicited events reported by subjects included mild to moderate injection site reactions and mild or moderate systemic symptoms at a frequency similar to the commercial vaccine. No serious adverse events were reported.
The ongoing phase 1, randomized, double-blind, active-controlled, dose-escalation study is assessing the safety and immunogenicity of P ertussis A cellular V accine A djuvanted with TQL-1055 (PAVA). It has fully enrolled 72 healthy adults 18-50 years of age and is evaluating six escalating dose levels from 25 to 800 mcg of TQL-1055, co-administered with a commercial pertussis vaccine. The primary endpoints of the study are safety and tolerability. Further data will be presented at IDWeek 2021.
About Pertussis: Commonly known as whooping cough, pertussis is a respiratory illness that spreads from person to person. Vaccination against pertussis occurs throughout life and is recommended in many countries for all children and adults. Reported annual cases of pertussis in the United States have increased 10-fold between the 1970s and 2010s, revealing the need for more effective vaccines and vaccination.
About TQL-1055 : TQL-1055 is a rationally designed, semi-synthetic analogue of the saponin adjuvant QS-21 that is designed to have improved tolerability and provide the same strong immune response as QS-21. Adjuvance has retained the desirable properties of, and eliminated several challenges with QS-21. TQL-1055 is a semi-synthetic molecule whose efficient synthesis uses raw material from leaves and branches of the Quillaja saponaria tree, making it available in greater quantities than the source material for other saponin adjuvants. TQL-1055 has shown favorable tolerability and a strong immune response in a clinical trial. With TQL-1055 as the foundation, Adjuvance is designing new combination adjuvants to produce different types of immune responses.
About saponin adjuvants : Saponin adjuvants are potent immune stimulators and important components of licensed and clinically-advanced infectious disease vaccines including those against shingles, malaria, COVID-19 and influenza. Saponin adjuvants have also been studied in immuno-oncology applications. Existing saponin adjuvants are limited by poor clinical tolerability and inefficient manufacturing requirements. The natural source material in most saponin adjuvants is extracted from the inner lining of the bark of the Quillaja saponaria tree, resulting in a terminal harvest.
About Adjuvance Technologies : Adjuvance Technologies is a privately held clinical-stage biopharmaceutical company dedicated to empowering health through fundamental breakthroughs in adjuvant design, vaccine development, and manufacturing. Adjuvance creates and manufactures next generation proprietary adjuvants as the foundation of its vaccine pipeline and for other developers through licensing partnerships. Our vaccine candidates in pertussis and herpes zoster aim to provide a better experience for the recipient and the same protection against disease.
Headquartered in Lincoln, Nebraska, the company has received grant funding from the National Institute of Health (NIH) and closed a Series A investment by Morningside Venture Investments. For more information, visit www.adjuvancetechnologies.com and connect with us on Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210824005212/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting udvider sit udbud med LBC12.12.2025 11:09:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer gennem en samarbejdsaftale med LBC, en Portugal-baseret international virksomhed kendt for sin integrerede tilgang til forretningsoptimering, digital transformation og udvikling af menneskelig kapital, der kombinerer kreativitet og menneskelig etik med ai med henblik på at accelerere værdiskabelse. LBC blev stiftet i 2001 og bistår internationale organisationer, offentlige instanser og virksomheder inden for adskillige brancher, herunder finans, energi, TMT, transport og den offentlige sektor. LBC betjener kunder i Afrika, Nord- og Sydamerika samt Europa og leverer ydelser inden for management consulting, digital transformation, kapacitetsopbygning og ai-implementering. Virksomheden er kendt for en kultur præget af innovativ transformation med fokus på vedvarende resultater og hjælper kunder med at navigere i komplekse forandringer med målbar effekt. Nylige investeringer i enterprise AI styrker virksomhedens kompetencer inden for UX/UI, auto
INNIO to Supply Technology for a Landmark Project in Texas, Reinforcing Grid Stability12.12.2025 09:59:00 CET | Press release
INNIO Group, a leading energy solution and service provider, is collaborating with the U.S. power utility Greenville Electric Utility System (GEUS) on a landmark 104-megawatt (MW) power plant. The new plant is designed to help reinforce grid stability, cover peak loads, and enable greater integration of renewable energy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251211712708/en/ Jenbacher J920 FleXtra “This project is a milestone for Texas and for INNIO. With fast-start capability, flexibility, and sustainability, we are creating the energy infrastructure that modern grids need: reliable, growth-promoting, and supporting the expansion of renewables,” said Dr. Olaf Berlien, President and CEO of INNIO Group. Groundbreaking for the plant’s construction took place in early December, with commissioning scheduled for summer 2027. The groundbreaking marks the beginning of the largest installation to date of Jenbacher J920 FleX
Kioxia Develops Core Technology that Will Allow the Practical Implementation of High-density, Low-power 3D DRAM12.12.2025 06:24:00 CET | Press release
Showcase the technology of highly stackable oxide-semiconductor channel transistors Kioxia Corporation, a world leader in memory solutions, today announced the development of highly stackable oxide-semiconductor channel transistors that will enable the practical implementation of high-density, low-power 3D DRAM. This technology was presented at the IEEE International Electron Devices Meeting (IEDM) held in San Francisco, USA, on December 10, and has the potential to reduce power consumption across a wide range of applications, including AI servers and IoT components. In the era of AI, there is growing demand for DRAM with larger capacity and lower power consumption that can process large amounts of data. Traditional DRAM technology is reaching the physical limits of memory cell size scaling, prompting research into the 3D stacking of memory cells to provide additional capacity. The use of single-crystal silicon as the channel material for transistors in stacked memory cells, as is the
Andersen Global styrker sine juridiske kapaciteter med tilføjelsen af brasiliansk medlemsfirma11.12.2025 18:49:00 CET | Pressemeddelelse
Andersen Global udbygger sin juridiske platform i Brasilien, da Lotti e Araújo bliver et medlemsfirma, hvilket styrker organisationens kapacitet i Latinamerika. Lotti e Araújo blev stiftet for over 20 år siden og tilbyder omfattende juridisk rådgivning til brasilianske og multinationale klienter inden for en lang række brancher. Dets tværfaglige praksis omfatter selskabsret, skatteret, arbejdsret, retssager, inkasso og inddrivelse af gæld – samt specialiseret arbejde med at identificere skjulte aktiver og inddrive anke- og retsindskud i ældre sager. Firmaet håndterer også voldgift, forvaltningsret, udenlandske investeringer, fast ejendom, intellektuel ejendomsret, databeskyttelse og virksomhedsomstrukturering og tilbyder juridisk assistance inden for selskabsdannelse og repræsentation over for tilsynsmyndigheder. Teamet rådgiver klienter om forebyggende juridiske strategier og komplekse tvister for administrative organer og domstole i Brasilien. "Hos Lotti e Araújo bygger vores praksis
BEYOND Developments Reveals a New Vision for Purposeful Living on Dubai Islands with SIORA11.12.2025 18:02:00 CET | Press release
A 2M sqft masterplan inspired by Japanese garden principles, crafted around balance, clarity, and the quiet rhythm of coastal life BEYOND Developments, the bold and design-led real estate developer shaping next-generation waterfront destinations in the UAE, today unveiled SIORA, its first beachfront masterplan on Dubai Islands and the company’s second large-scale community within a year. The launch underscores BEYOND’s accelerated growth and strong alignment with Dubai’s future urban vision. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251211014389/en/ BEYOND Developments - SIORA Masterplan at sunset - Dubai Islands (Photo: AETOSWire) Spanning over 2M square feet, SIORA is conceived as a coastal sanctuary inspired by Japanese garden philosophies, including the pursuit of Ikigai, the Japanese concept of finding purpose and fulfilment in everyday life. In this context, it reflects a philosophy of creating spaces that bring c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom